Hepatocellular carcinoma: Prevention, detection and treatment ... in the real world

Internal Medicine Journal

Volumn 37, Issue 8, 2007, Pages 513-515

  Koorey, D ^a  

^a ROYAL PRINCE ALFRED HOSPITAL   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

AFLATOXIN; IODINATED POPPYSEED OIL I 131; PEGINTERFERON; RADIOPHARMACEUTICAL AGENT; RIBAVIRIN; UNCLASSIFIED DRUG;

CANCER DIAGNOSIS; CANCER PREVENTION; CANCER RISK; CANCER SURGERY; CANCER SURVIVAL; CANCER THERAPY; EDITORIAL; HEALTH EDUCATION; HEPATITIS B; HEPATITIS C; HUMAN; INTRAVENOUS DRUG ABUSE; LIVER CARCINOGENESIS; LIVER CELL CARCINOMA; LIVER RESECTION; LIVER TRANSPLANTATION; NONALCOHOLIC FATTY LIVER; PRIORITY JOURNAL; SUPERINFECTION; SURVIVAL RATE; SURVIVAL TIME; TREATMENT OUTCOME; VACCINATION; VIRUS CARCINOGENESIS; VIRUS TRANSMISSION;

CARCINOMA, HEPATOCELLULAR; HEPATITIS, VIRAL, HUMAN; HUMANS; LIVER NEOPLASMS;

EID: 34447550742     PISSN: 14440903     EISSN: 14455994     Source Type: Journal    
DOI: 10.1111/j.1445-5994.2007.01439.x     Document Type: Editorial

References (28)

1. Bosch FX, Ribes J, Diaz M, Cleries R. Primary liver cancer: worldwide incidence and trends. Gastroenterology 2004 127:S5 S16.
2. El-Serag H, Mason A. Rising incidence of hepatocellular carcinoma in the United States. N Engl J Med 1999 340:745 50.
3. Law M, Roberts S, Dore G, Kaldor J. Primary hepatocellular carcinoma in Australia, 1978-1997: increasing incidence and mortality. Med J Aust 2000 173:403 5.
4. Caldwell S, Crespo D, Kang H, Al-Osaimi A. Obesity and hepatocellular carcinoma. Gastroenterology 2004 127:S97 S103.
5. Chang M, Chen C, Lai M, Hsu H, Wu T, Kong M et al. Universal hepatitis B vaccination in Taiwan and the incidence of hepatocellular carcinoma in children. N Engl J Med 1997 336:1855 9.
6. Department of Health NSW. Hepatitis B vaccination policy. January 2005. Available from URL:http://www.health.nsw.gov.au/policies/PD/2005/pdf/PD2005_222. pdf [Accessed June 2007].
7. Kensler T, Egner P, Wang J, Zhu Y, Zhang B, Lu P et al. Chemoprevention of hepatocellular carcinoma in aflatoxin endemic areas. Gastroenterology 2004 127:S310 18.
8. Nishiguchi S, Kuroki T, Nakatani S, Morimoto H, Takeda T, Nakajima S et al. Randomised trial of effects of interferon alpha on incidence of hepatocellular carcinoma in chronic active hepatitis C with cirrhosis. Lancet 1995 346:1051 5.
9. International Interferon Alpha Hepatocellular Carcinoma Study Group. Effect of interferon alpha on progression of cirrhosis to hepatocellular carcinoma: a retrospective cohort study. Lancet 1998 351:1535 9.
10. Gramenzi A, Andreone P, Fiorino S, Camma C, Giunta M, Magalotti D et al. Impact of interferon therapy on the natural history of hepatitis C virus related cirrhosis. Gut 2001 48:843 8.
11. Nishiguchi S, Shiomi S, Nakatani S, Takeda T, Fukuda K, Tamori A et al. Prevention of hepatocellular carcinoma in patients with chronic active hepatitis C and cirrhosis. Lancet 2001 357:196 7.
12. Heathcote E. Prevention of hepatitis C virus-related hepatocellular carcinoma. Gastroenterology 2004 127:S294 S302.
13. Colonna R, Genovesi E, Medina I, Lamb L, Durham S, Huang M et al. Long-term entecavir treatment results in sustained antiviral efficacy and prolonged life span in the woodchuck model of chronic hepatitis infection. JID 2001 184:1236 45.
14. Liaw Y, Sung J, Chow W, Farrell G, Lee C, Yuen H et al. Lamivudine for patients with chronic hepatitis B and advanced liver disease. N Engl J Med 2004 351:1521 31.
15. Lok A. Prevention of hepatits B virus-related hepatocellular carcinoma. Gastroenterology 2004 127:S303 9.
16. Barton J, McDonnell S, Adams P, Brissot P, Powell L, Edwards C et al. Management of hemochromatosis. Ann Intern Med 1998 129:932 9.
17. Yuen M, Cheng C, Lauder I, Lam S, Ooi C, Lai C. Early detection of hepatocellular carcinoma increases the chance of treatment: Hong Kong experience. Hepatology 2000 31:330 5.
18. Zhang B, Yang B, Tang Z. Randomized controlled trial of screening for hepatocellular carcinoma. J Cancer Res Clin Oncol 2004 130:417 22.
19. Poustchi H, George J, Labio E, Coverdale S, Carney R, Perry J et al. Screening for liver cancer: feasibility of a randomized controlled trial. Hepatology 2005 42 Suppl 1:376A.
20. McCaughan G, Koorey D, Strasser S. Hepatocellular carcinoma: current approaches to diagnosis and management. Intern Med J 2002 32:394 400.
21. Tang Z, Yu Y, Zhou X, Ma Z, Yang R, Lu J et al. Surgery of small hepatocellular carcinoma: analysis of 144 cases. Cancer 1989 64:536 41.
22. Lau W, Leung T, Ho S, Chan M, Machin D, Lau J et al. Adjuvant intra-arterial iodine-131-labelled lipiodol for resectable hepatocellular carcinoma: a prospective randomised trial. Lancet 1999 353:797 801.
23. Mazzaferro V, Regalia E, Doci R, Andreola S, Pulvirenti A, Bozzetti F et al. Liver transplantation for the treatment of small hepatocellular carcinomas in patients with cirrhosis. N Engl J Med 1996 334:693 9.
24. Lin S, Lin C, Lin C, Hsu C, Chen Y. Randomised controlled trial comparing percutaneous radiofrequency thermal ablation, percutaneous ethanol injection, and percutaneous acetic acid injection to treat hepatocellular carcinoma of 3 cm or less. Gut 2005 54:1151 6.
25. Llovet J, Real M, Montana X, Planas R, Coll S, Aponte J et al. Arterial embolisation or chemoembolisation versus symptomatic treatment in patients with unresectable hepatocellular carcinoma: a randomised controlled trial. Lancet 2002 359:1734 9.
26. Carr B. Hepatocellular carcinoma: current management and future trends. Gastroenterology 2004 127:S218 24.
27. Fabregat I, Roncero C, Fernandez M. Survival and apoptosis: a dysregulated balance in liver cancer. Liver Int 2007 27:155 62.
28. Gellert L, Jalaludin B, Levy M. Hepatocellular carcinoma in Sydney South West: late symtomatic presentation and poor outcome for the majority. Intern Med J 2007 37:516 22.